AstraZeneca (AZN) has entered a global licensing agreement to develop and commercialize Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, the company said Tuesday.
The company will pay Dizal $600 million upfront and up to $900 million in additional development, regulatory and sales milestones, plus tiered royalties on global sales, it said.
The transaction is expected to close in H2, subject to customary conditions and regulatory approvals.
AstraZeneca shares were 1.6% lower in Tuesday premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments